CytomX Therapeutics's top three insider shareholders as of September 29, 2026 are Sean A. Mccarthy (Ceo, 1.08Mn shares), Sean A. Mccarthy (Ceo, 987.89K shares), Marcia Belvin (Svp, Chief Scientific Officer, 300.76K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Sean A. Mccarthy | Ceo | 2,066,813 | 0 | 2,066,813 | 61.8% | 19 Mar, 2026 |
| 2 | Marcia Belvin | Svp, Chief Scientific Officer | 300,760 | 0 | 300,760 | 9.0% | 19 Mar, 2026 |
| 3 | Christopher Ogden | Chief Financial Officer | 295,324 | 0 | 295,324 | 8.8% | 17 Jun, 2026 |
| 4 | Yu-Waye Chu | Chief Medical Officer | 189,446 | 0 | 189,446 | 5.7% | 19 Mar, 2026 |
| 5 | Lloyd A Rowland | General Counsel | 120,594 | 0 | 120,594 | 3.6% | 20 Mar, 2025 |
| 6 | Jeffrey B Landau | Chief Business Officer | 119,056 | 0 | 119,056 | 3.6% | 22 Aug, 2024 |
| 7 | Alejandra Carvajal | Chief Legal Officer | 100,000 | 0 | 100,000 | 3.0% | 05 Aug, 2026 |
| 8 | Amy C. Peterson | Evp, Chief Development Officer | 58,433 | 0 | 58,433 | 1.7% | 20 Mar, 2023 |
| 9 | Carlos Campoy | Chief Financial Officer | 38,224 | 0 | 38,224 | 1.1% | 20 Mar, 2023 |
| 10 | Alison L. Hannah | Chief Medical Officer | 31,898 | 0 | 31,898 | 1.0% | 21 Jul, 2022 |
| 11 | Rachael Lester | Chief Business Officer | 20,000 | 0 | 20,000 | 0.6% | 04 Feb, 2026 |
| 12 | Elaine V Jones | Director | 5,142 | 0 | 5,142 | 0.2% | 31 Mar, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 03 Aug, 2026 | Alejandra Carvajal | Chief Legal Officer | Acquired A | 100,000 | $0.00 | $0 | 100,000 | Direct |
| 03 Aug, 2026 | Alejandra Carvajal | Chief Legal Officer | Acquired A | 450,000 | $0.00 | $0 | 450,000 | Direct |
| 24 Jul, 2026 | Charles S. Fuchs | Director | Acquired A | 118,000 | $0.00 | $0 | 118,000 | Direct |
| 17 Jun, 2026 | Zhen Su | Director | Acquired A | 59,000 | $0.00 | $0 | 59,000 | Direct |
| 17 Jun, 2026 | Elaine V Jones | Director | Acquired A | 59,000 | $0.00 | $0 | 59,000 | Direct |
| 17 Jun, 2026 | Alan Ashworth | Director | Acquired A | 59,000 | $0.00 | $0 | 59,000 | Direct |
| 17 Jun, 2026 | Matthew P. Young | Director | Acquired A | 59,000 | $0.00 | $0 | 59,000 | Direct |
| 17 Jun, 2026 | James R Meyers | Director | Acquired A | 59,000 | $0.00 | $0 | 59,000 | Direct |
| 17 Jun, 2026 | Halley E Gilbert | Director | Acquired A | 59,000 | $0.00 | $0 | 59,000 | Direct |
| 17 Jun, 2026 | Mani Mohindru | Director | Acquired A | 59,000 | $0.00 | $0 | 59,000 | Direct |
| 15 Jun, 2026 | Christopher Ogden | Chief Financial Officer | Disposed S | 1,624 | $3.05 | $4.95K | 295,324 | Direct |
| 17 Mar, 2026 | Yu-Waye Chu | Chief Medical Officer | Disposed S | 21,279 | $6.42 | $136.68K | 189,446 | Direct |
| 17 Mar, 2026 | Sean A. Mccarthy | Ceo | Disposed S | 118,969 | $6.42 | $764.14K | 1,078,922 | Direct |
| 17 Mar, 2026 | Marcia Belvin | Svp, Chief Scientific Officer | Disposed S | 31,492 | $6.42 | $202.27K | 300,760 | Direct |
| 17 Mar, 2026 | Christopher Ogden | Chief Financial Officer | Disposed S | 19,323 | $6.42 | $124.11K | 296,948 | Direct |
| 02 Feb, 2026 | Christopher Ogden | Chief Financial Officer | Acquired A | 90,000 | $0.00 | $0 | 316,271 | Direct |
| 02 Feb, 2026 | Sean A. Mccarthy | Ceo | Acquired A | 210,000 | $0.00 | $0 | 1,197,891 | Direct |
| 02 Feb, 2026 | Rachael Lester | Chief Business Officer | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 02 Feb, 2026 | Yu-Waye Chu | Chief Medical Officer | Acquired A | 75,000 | $0.00 | $0 | 210,725 | Direct |
| 02 Feb, 2026 | Marcia Belvin | Svp, Chief Scientific Officer | Acquired A | 60,000 | $0.00 | $0 | 332,252 | Direct |